A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs EDP 322 (Primary)
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 07 Oct 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT00989872).
- 07 Oct 2009 Planned number of patients added (67) added as reported by ClinicalTrials.gov.
- 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.